drugset / Trial / NCT03122548
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior chemotherapy regimens for advanced disease.
Timeline
- Start
- 2017-08-14
- Primary completion
- 2017-12-27
- Completion
- 2018-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRS-207 | Vaccine | 1e+09 unknown | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |